Lung‐Ji Chang

5.1k total citations
132 papers, 4.2k citations indexed

About

Lung‐Ji Chang is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Lung‐Ji Chang has authored 132 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 51 papers in Molecular Biology and 41 papers in Genetics. Recurrent topics in Lung‐Ji Chang's work include CAR-T cell therapy research (58 papers), Virus-based gene therapy research (35 papers) and Immunotherapy and Immune Responses (18 papers). Lung‐Ji Chang is often cited by papers focused on CAR-T cell therapy research (58 papers), Virus-based gene therapy research (35 papers) and Immunotherapy and Immune Responses (18 papers). Lung‐Ji Chang collaborates with scholars based in United States, China and Canada. Lung‐Ji Chang's co-authors include Don Ganem, Harold Varmus, C. Martin Stoltzfus, Russell C. Hirsch, Fumiko Higashikawa, Dimiter S. Dimitrov, Robert Blumenthal, R L Willey, M A Martin and Hironori Sato and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Lung‐Ji Chang

126 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lung‐Ji Chang United States 35 1.8k 1.1k 992 794 747 132 4.2k
Heidi Stuhlmann United States 34 3.8k 2.1× 732 0.7× 1.3k 1.3× 1.7k 2.1× 570 0.8× 71 7.1k
Estuardo Aguilar-Córdova United States 39 2.5k 1.4× 1.5k 1.4× 2.7k 2.7× 831 1.0× 445 0.6× 99 4.6k
Toni Cathomen Germany 44 5.3k 3.0× 721 0.7× 2.2k 2.2× 578 0.7× 1.1k 1.5× 161 7.0k
William M. Rehrauer United States 26 2.0k 1.1× 408 0.4× 832 0.8× 706 0.9× 442 0.6× 55 3.5k
Alan R. Davis United States 41 1.6k 0.9× 714 0.7× 1.3k 1.3× 569 0.7× 1.3k 1.7× 110 4.3k
Michael Rosenzweig United States 36 1.9k 1.0× 1.2k 1.2× 515 0.5× 2.0k 2.5× 1.1k 1.4× 99 5.4k
Yosef Refaeli United States 22 1.4k 0.8× 695 0.7× 333 0.3× 1.9k 2.4× 463 0.6× 38 3.7k
Douglas J. Jolly United States 37 3.3k 1.9× 857 0.8× 2.5k 2.5× 620 0.8× 672 0.9× 108 4.8k
Premlata Shankar United States 35 4.9k 2.7× 549 0.5× 1.2k 1.2× 2.3k 2.9× 784 1.0× 68 7.6k
N. Manjunath United States 36 3.2k 1.8× 730 0.7× 692 0.7× 3.2k 4.1× 556 0.7× 67 6.8k

Countries citing papers authored by Lung‐Ji Chang

Since Specialization
Citations

This map shows the geographic impact of Lung‐Ji Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lung‐Ji Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lung‐Ji Chang more than expected).

Fields of papers citing papers by Lung‐Ji Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lung‐Ji Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lung‐Ji Chang. The network helps show where Lung‐Ji Chang may publish in the future.

Co-authorship network of co-authors of Lung‐Ji Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Lung‐Ji Chang. A scholar is included among the top collaborators of Lung‐Ji Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lung‐Ji Chang. Lung‐Ji Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Hongwei, Yingying Wang, Rui Zhang, & Lung‐Ji Chang. (2025). The development of an advanced lentiviral gene therapy for beta-thalassemia. Biochemical and Biophysical Research Communications. 793. 152963–152963.
2.
Chung, Tsai‐Hua, et al.. (2021). Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A. Journal of Biological Chemistry. 297(6). 101397–101397. 10 indexed citations
3.
Yu, Lihua, Lulu Huang, Xiaorong Lai, et al.. (2021). GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. Journal of Cancer Research and Clinical Oncology. 148(10). 2643–2652. 57 indexed citations
4.
Ma, Lian, et al.. (2021). Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. International Immunopharmacology. 96. 107731–107731. 18 indexed citations
5.
Trakarnsanga, Kongtana, et al.. (2020). Multilineage differentiation potential of hematoendothelial progenitors derived from human induced pluripotent stem cells. Stem Cell Research & Therapy. 11(1). 481–481. 23 indexed citations
6.
Zhou, Xuan, Sanfang Tu, Chunsheng Wang, et al.. (2020). Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Frontiers in Immunology. 11. 564099–564099. 41 indexed citations
7.
Zhang, Hui, et al.. (2020). Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia. Frontiers in Oncology. 10. 685–685. 40 indexed citations
8.
Qi, Xiaoping, et al.. (2018). Improving the Transduction of Bone Marrow-Derived Cells with an Integrase-Defective Lentiviral Vector. PMC. 1 indexed citations
9.
Zhang, Qin, Yuchen Liu, Li Yan, et al.. (2017). Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma. Blood. 130. 5154–5154. 5 indexed citations
10.
11.
Li, Hua, Lung‐Ji Chang, Debbie Neubauer, David Muir, & Margaret R. Wallace. (2016). Immortalization of human normal and NF1 neurofibroma Schwann cells. Laboratory Investigation. 96(10). 1105–1115. 64 indexed citations
12.
13.
Patel, Ekta, et al.. (2012). Regulation of in vitro human T cell development through interleukin-7 deprivation and anti-CD3 stimulation. BMC Immunology. 13(1). 46–46. 9 indexed citations
14.
Li, Hong, Yuanqing Lu, Rafal P. Witek, et al.. (2010). Ex Vivo Transduction and Transplantation of Bone Marrow Cells for Liver Gene Delivery of α1-Antitrypsin. Molecular Therapy. 18(8). 1553–1558. 13 indexed citations
15.
16.
Han, Shuhong, et al.. (2009). Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. Journal of Hematology & Oncology. 2(1). 34–34. 12 indexed citations
17.
Moreb, Jan S., et al.. (2007). ALDH isozymes downregulation effects on cell growth and gene expression in lung cancer cell lines. Clinical Cancer Research. 13. 14 indexed citations
18.
Yang, Qing, et al.. (2007). Overlapping enhancer/promoter and transcriptional termination signals in the lentiviral long terminal repeat. Retrovirology. 4(1). 4–4. 21 indexed citations
19.
He, Jin & Lung‐Ji Chang. (2004). Functional characterization of hepatoma‐specific stem cell antigen‐2. Molecular Carcinogenesis. 40(2). 90–103. 13 indexed citations
20.
Higashikawa, Fumiko & Lung‐Ji Chang. (2001). Kinetic Analyses of Stability of Simple and Complex Retroviral Vectors. Virology. 280(1). 124–131. 154 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heidi Stuhlmann Breakdown of academic impact, for papers by Estuardo Aguilar-Córdova Breakdown of academic impact, for papers by Toni Cathomen Breakdown of academic impact, for papers by William M. Rehrauer Breakdown of academic impact, for papers by Alan R. Davis Breakdown of academic impact, for papers by Michael Rosenzweig Breakdown of academic impact, for papers by Yosef Refaeli Breakdown of academic impact, for papers by Douglas J. Jolly Breakdown of academic impact, for papers by Premlata Shankar Breakdown of academic impact, for papers by N. Manjunath
Rankless by CCL
2026